Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
79.4M
-
Number of holders
-
170
-
Total 13F shares, excl. options
-
73M
-
Shares change
-
+1.03M
-
Total reported value, excl. options
-
$2.09B
-
Value change
-
+$38.3M
-
Put/Call ratio
-
2.58
-
Number of buys
-
78
-
Number of sells
-
-72
-
Price
-
$28.69
Significant Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) as of Q3 2024
198 filings reported holding AKRO - Akero Therapeutics, Inc. - COMMON STOCK as of Q3 2024.
Akero Therapeutics, Inc. - COMMON STOCK (AKRO) has 170 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 73M shares
of 79.4M outstanding shares and own 91.97% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (7.9M shares), JANUS HENDERSON GROUP PLC (7.08M shares), RTW INVESTMENTS, LP (5.92M shares), BlackRock, Inc. (5.75M shares), GENERAL ATLANTIC, L.P. (5.23M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.81M shares), VANGUARD GROUP INC (3.68M shares), ALKEON CAPITAL MANAGEMENT LLC (3.33M shares), STATE STREET CORP (2.5M shares), and ALLIANCEBERNSTEIN L.P. (2.02M shares).
This table shows the top 170 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.